UMIN ID: UMIN000000928
Registered date:25/12/2007
Chronotherapy of methotrexate in patients with rheumatic arthritis
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | rheumatoid arthritis |
| Date of first enrollment | 2007/11/01 |
| Target sample size | 20 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | the dosing schedule used commonly in clinical practice vs. chronotherapy |
Outcome(s)
| Primary Outcome | Disease Activity Score (DAS) 28 adverse effects mHAQ |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Patients were excluded from the study if any of the following criteria applied: (1) concurrent pregnancy, (2) the presence of serious complications in the heart, lung, kidney, etc., (3) perform of surgical operation for rheumatoid arthritis within a period of 6 months before administration (4) use of glucocorticoids(10.1 mg/day) within a period of one month before administration or (5) any other reason for which the investigator judged the patient to be unfit for study. |
Related Information
| Primary Sponsor | Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Health and Labour Sciences Research Grants,Japan Research Foundation For Clinical Pharmacology |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Hideto To |
| Address | Japan |
| Telephone | 076-415-8811 |
| hide-to@umin.net | |
| Affiliation | Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama 2630 Sugitani, Toyama |
| scientific contact | |
| Name | Hideto To |
| Address | 2630 Sugitani, Toyama Japan |
| Telephone | |
| Affiliation | Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama Department of Medical Pharmaceutics |